-
Board Certification
American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Patient Rating
5.0 /5( out of 47 reviews )The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.
The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient Comments
Patient comments are gathered from our patient experience survey and displayed in their entirety.
Patients are de-identified for confidentiality and patient privacy.October 19, 2024HUNTSMAN CANCER CENTERDr. Patel is one of the finest MD's I've every had. She is wonderful!
October 04, 2024HUNTSMAN CANCER CENTERVery thorough and compassionate
September 26, 2024HUNTSMAN CANCER CENTERDoctor Patel is an excellent doctor.
September 16, 2024HUNTSMAN CANCER CENTERDr Ami B Patel, MD, has been my oncologist for just shy of five years. She is very friendly, kind, caring and gentle. She always greets me with a wonderful smile and makes me feel so comfortable. Dr Patel listens and explains things so I understand. She obviously cares about me and my health journey. I'm so grateful to have Dr Patel as my oncologist.
July 27, 2024HUNTSMAN CANCER CENTERVery good knowledge on CMML.
July 26, 2024HUNTSMAN CANCER CENTERExcellent hermatogist would recommend to friends and family very responsive and knowledgeable about CMML
July 03, 2024HUNTSMAN CANCER CENTERDr. Patel is a wonderful doctor. She truly cares about her patients as individuals and anticipates their needs. She is amazing at explaining things and taking time to ensure patient understanding. She is truly a gift to her hematology practice. Her staff is equally amazing!
June 14, 2024HUNTSMAN CANCER CENTERVery thorough and compassion care
June 08, 2024HUNTSMAN CANCER CENTERI'm a very satisfied and confident in my treatment with Dr Patel. I would recommend her and the whole organization. I have strong confidence in her depth of knowledge and up to date insights for the latest developments for my condition and those of others. I appreciate that she is involved in research also which helps the above I am sure. I hope the entire organization values her greatly and I suspect that it does!
-
Board Certification and Academic Information
Academic Departments Internal Medicine -Primary Academic Divisions Hematology & Hematologic Malignancies
Board Certification American Board of Internal Medicine (Internal Medicine)American Board of Internal Medicine (Sub: Hematology)American Board of Internal Medicine (Sub: Medical Oncology)Education history
Fellowship Hematology/Oncology Research - ÑÇÖÞ×ÔοÊÓƵ of Utah Advanced Fellow Hematology/Oncology Fellowship Program - ÑÇÖÞ×ÔοÊÓƵ of Utah School of Medicine Chief Fellow Fellowship Hematology/Oncology - ÑÇÖÞ×ÔοÊÓƵ of Utah School of Medicine Fellow Internal Medicine - McGaw Medical Center of Northwestern ÑÇÖÞ×ÔοÊÓƵ Resident Internship Internal Medicine - McGaw Medical Center of Northwestern ÑÇÖÞ×ÔοÊÓƵ Intern Medicine - Northwestern ÑÇÖÞ×ÔοÊÓƵ Feinberg School of Medicine M.D. Undergraduate Biology - Northwestern ÑÇÖÞ×ÔοÊÓƵ B.S. Selected Publications
Journal Article
- Patel AB, Deininger MW (2020). Genetic complexity of chronic myelomonocytic leukemia. Leuk Lymphoma, 62(5), 1031-1045. ()
- Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, Ahmann JM, Senina AV, Vellore NA, Jones CL, Zabriskie MS, Than H, Xiao MJ, van Scoyk A, Patel AB, Clair PM, Heaton WL, Owen SC, Andersen JL, Egbert CM, Reisz JA, DAlessandro A, Cox JE, Gantz KC, Redwine HM, Iyer SM, Khorashad JS, Rajabi N, Olsen CA, OHare T, Deininger MW (2019). SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA. Blood Cancer Discov, 2(3), 266-287. ()
- Patel AB, Pomicter AD, Yan D, Eiring AM, Antelope O, Schumacher JA, Kelley TW, Tantravahi SK, Kovacsovics TJ, Shami PJ, OHare T, Deininger MW (2020). Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms. Leukemia, 34(11), 2981-2991. ()
- Patel AB, Franzini A, Leroy E, Kim SJ, Pomicter AD, Genet L, Xiao M, Yan D, Ahmann JM, Agarwal AM, Clair P, Addada J, Lambert J, Salmon M, Gleich GJ, Cross NCP, Constantinescu SN, OHare T, Prchal JT, Deininger MW (2019). JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood, 134(26), 2388-2398. ()
- Antelope O, Vellore NA, Pomicter AD, Patel AB, Van Scoyk A, Clair PM, Deininger MW, OHare T (2019). BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia. Exp Hematol, 77, 36-40.e2. ()
- Patel AB, Miles RR, Deininger MW (2019). Lysozyme nephropathy in chronic myelomonocytic leukemia. Clin Case Rep, 7(6), 1263-1264. ()
- Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW (2019). Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv, 3(7), 952-955. ()
- Patel AB, Chen YH, Zhang Y, Frankfurt O, Winter JN (2014). Achievement of morphologic and cytogenetic remission with single-agent hydroxyurea in a patient with acute myeloid leukemia with inv(16). Leuk Lymphoma, 56(3), 817-9. ()
-
News & Podcasts
( out of 47 reviews )